Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 82,127 shares, a drop of 49.5% from the October 15th total of 162,704 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average daily trading volume, of 1,493,800 shares, the days-to-cover ratio is currently 0.1 days.
Analysts Set New Price Targets
SLXN has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Wall Street Zen upgraded shares of Silexion Therapeutics to a “hold” rating in a research note on Saturday. Finally, Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.
Get Our Latest Research Report on Silexion Therapeutics
Silexion Therapeutics Stock Down 2.1%
SLXN traded down $0.04 during midday trading on Tuesday, reaching $1.72. 11,696 shares of the company’s stock were exchanged, compared to its average volume of 134,329. The business has a 50-day simple moving average of $5.57 and a two-hundred day simple moving average of $137.78. The firm has a market capitalization of $396,290.00, a price-to-earnings ratio of -0.04 and a beta of -0.30. Silexion Therapeutics has a one year low of $1.67 and a one year high of $777.12.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($13.70) EPS for the quarter, topping the consensus estimate of ($218.40) by $204.70. As a group, research analysts anticipate that Silexion Therapeutics will post -112.71 EPS for the current fiscal year.
About Silexion Therapeutics
Silexion Therapeutics is an Israel-based clinical-stage biotechnology company developing RNA interference (RNAi) treatments for cancers associated with mutations in the KRAS gene. Its approach is designed to reduce the activity of cancer-related genes rather than target tumors with conventional drug therapies. The company’s lead candidate, SIL-204, is being developed for pancreatic cancer. It is an investigational treatment, and Silexion has not established a commercial product portfolio. Silexion’s work is focused on research and clinical development; its treatments are not approved for routine commercial use.
Further Reading
- Five stocks we like better than Silexion Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
